Osimertinib

🧮 Dose calculator

Lung cancer (small-cell and non-small-cell) · Regimen source: FDA Tagrisso · 2.3

• • Only under an oncologist; continue until progression or unacceptable toxicity. Dose adjustments for toxicity and interactions per label. FDA Tagrisso · 2.3
• • Adjuvant after resection: up to 3 years. Select patients with an FDA-approved test. FDA Tagrisso · 2.3FDA Tagrisso · 2.2

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyDangerous / avoid

  Label: can cause fetal harm. Dangerous in pregnancy. FDA Tagrisso · 8.1

  “Risk Summary Based on data from animal studies and its mechanism of action [see Clinical Pharmacology (12.1) ] , TAGRISSO can cause fetal harm when administered to a pregnant woman.”

• 🤱 BreastfeedingDangerous / avoid

  Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Tagrisso · 8.2

  “Because of the potential for serious adverse reactions in breastfed infants from osimertinib, advise women not to breastfeed during treatment with TAGRISSO and for 2 weeks after the last dose.”

• 👶 ChildrenSafety not established

  Label: safety and effectiveness in children have not been established. FDA Tagrisso · 8.4

  “The safety and effectiveness of TAGRISSO in pediatric patients have not been established.”

• 👴 Older adultsNo specific problem stated

  Label: no specific difference or dose adjustment stated for older adults. FDA Tagrisso · 8.5

  “No overall differences in safety or effectiveness were observed between patients 65 years or older and younger patients.”

• ⚥ Females & males of reproductive potentialUse with caution

  Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Tagrisso · 8.3

  “Contraception Females Advise females of reproductive potential to use effective contraception during treatment with TAGRISSO and for 6 weeks after the last dose [see Use in Specific Populations (8.1) ] .”